QQ客服 官方微博 反馈留言

	Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer
	Jinyu Li PhD,; Junhao You MD,; Wen Si MD,; Yanyun Zhu MD,; Yi Chen MD,; Bo Yang PhD,; Chun Han MD,; Ruixia Linghu MD,; Xingyang Zhang MD,; Shunchang Jiao PhD,
刊名	Medicine (Baltimore)
	2015
卷号	Vol.94 No.41页码:e1340
ISSN号	0151-2137
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/1862670
专题	南开大学
作者单位	From the Department of Medical Oncology , Chinese PLA General Hospital, Beijing Department of Medical Oncology , Hainan Branch of PLA General Hospital, Sanya School of Medicine , Nankai University, Tianjin and Medical Center of Tsinghua University , Beijing, China.
推荐引用方式 GB/T 7714	Jinyu Li PhD,,Junhao You MD,,Wen Si MD,,et al. Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer[J]. Medicine (Baltimore),2015,Vol.94 No.41:e1340.
APA	Jinyu Li PhD,.,Junhao You MD,.,Wen Si MD,.,Yanyun Zhu MD,.,Yi Chen MD,.,...&Junlan Yang PhD.(2015).Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer.Medicine (Baltimore),Vol.94 No.41,e1340.
MLA	Jinyu Li PhD,,et al."Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer".Medicine (Baltimore) Vol.94 No.41(2015):e1340.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。